Alivus Life Sciences reported a strong performance for the second quarter of FY27, with revenue increasing by 16.0% year-over-year to Rs. 6,820 Mn. EBITDA saw a substantial jump of 47.0% to Rs. 2,851 Mn, with margins reaching a record high of 41.8%. Profit After Tax (PAT) also grew significantly by 51.3% to Rs. 1,968 Mn. The company also highlighted robust cash flow generation and a healthy balance sheet.
Alivus Life Sciences Reports Strong Q2 FY27 Financials
Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) today announced its financial results for the second quarter and half-year ended September 30, 2026. The company delivered a robust performance, marked by significant year-over-year growth in key financial metrics.
Q2 FY27 Performance Highlights
Revenue from operations for Q2 FY27 stood at Rs. 6,820 Mn, representing a growth of 16.0% compared to the same period last year. This growth was primarily driven by broad-based momentum in the non-GPL business, which expanded by 20.8% year-over-year.
EBITDA for Q2 FY27 showed a remarkable increase of 47.0% year-over-year, reaching Rs. 2,851 Mn. The EBITDA margin was at a record high of 41.8%, up 520 basis points quarter-over-quarter and 880 basis points year-over-year. This improvement was attributed to a favourable product mix, new launches, and benefits from operating leverage.
Profit After Tax (PAT) for Q2 FY27 grew by 51.3% year-over-year to Rs. 1,968 Mn. PAT margins were reported at 28.9%, up 390 basis points quarter-over-quarter and 680 basis points year-over-year.
H1 FY27 Performance
For the first half of FY27 (H1 FY27), revenue from operations was Rs. 13,224 Mn, showing an 11.1% year-over-year growth.
EBITDA for H1 FY27 stood at Rs. 5,192 Mn, a substantial increase of 38.4% year-over-year, with margins at 39.3%, up 780 basis points year-over-year.
PAT for H1 FY27 reached Rs. 3,569 Mn, a growth of 41.9% year-over-year, with margins at 27.0%, up 590 basis points year-over-year.
Cash Flow and Financial Flexibility
The company generated a strong free cash flow of Rs. 2,702 Mn during the period. As of September 30, 2026, Alivus Life Sciences had Cash and Cash Equivalents, including short-term investments, totaling Rs. 10,116 Mn. The CFO highlighted healthy operating performance translated into robust cash generation, with cash flow from operations of Rs. 270 crores during H1FY27. Cash and cash equivalents of Rs. 1,012 crores provide ample financial flexibility for growth initiatives while maintaining a debt-free balance sheet.
Additional Highlights
The company continues to strengthen its intellectual property, with a cumulative filing of 630 DMF/CEP filings as of September 30, 2026. In FY26, 15 patents were filed and 4 granted. In H1FY27, an additional 10 patents were filed and 3 granted, bringing the cumulative patent grants to 88.
The HP API portfolio comprises 30 APIs in the active grid, with 14 products validated and seven in advanced development stages.
Capex Update
Construction for Phase 1 (340 KL capacity) and Phase 2 (125 KL capacity) of the Solapur facility is underway and expected to be completed in Q3 FY27 and Q4 FY27, respectively. The new R&D facility in Taloja is also progressing, aiming to enhance research capabilities in various advanced chemistry areas.
Source: BSE
